Recent research suggests retatrutide, a innovative dual-action peptide, could be a major development in metabolic management. This compound works by targeting both the GLP-1 and GIP receptors, conceivably offering a enhanced effect than current GLP-1 receptor medications . Early clinical tria… Read More